MAPT and tauopathy: Recently, we revealed that cis conformation of phosphorylated Thr231 of Tau (cis P-tau) is a central circulating etiological driver in PE, and the cis P-tau specific monoclonal antibody (cis mAb) has potential for early PE diagnosis and treatment (Jash et al., 2023), suggesting that PE may be another non-conventional tauopathy.